RNTX (Rein Therapeutics) Cyclically Adjusted Book per Share: $3.74 (As of Mar. 2026)


RNTX Rein Therapeutics Inc RNTX
30 GF Score
Price $0.99
! 1 Warning Sign
View Full Analysis

What is Rein Therapeutics Cyclically Adjusted Book per Share?

Rein Therapeutics RNTX +1.38% 30 Cyclically Adjusted Book per Share is $3.74 as of Mar. 2026. GuruFocus rates RNTX with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Rein Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was $-1.192. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $3.74 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-04), Rein Therapeutics's current stock price is $0.9906. Rein Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $3.74. Rein Therapeutics's Cyclically Adjusted PB Ratio of today is 0.26.

During the past 11 years, the highest Cyclically Adjusted PB Ratio of Rein Therapeutics was 0.26. The lowest was 0.00. And the median was 0.00.


Rein Therapeutics  (NAS:RNTX) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Rein Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.9906/3.74
=0.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Cyclically Adjusted PB Ratio of Rein Therapeutics was 0.26. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Rein Therapeutics Cyclically Adjusted Book per Share Related Terms


Rein Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Rein Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rein Therapeutics Cyclically Adjusted Book per Share Chart

Rein Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 3.80

Rein Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -0.92 3.80 3.74

RNTX vs IBIO, RANI, OSTX: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Rein Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rein Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rein Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Rein Therapeutics's Cyclically Adjusted PB Ratio falls into.


RNTX
30GF Score
Rein Therapeutics Inc RNTX
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rein Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Rein Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-1.192/330.2130*330.2130
=-1.192

Current CPI (Mar. 2026) = 330.2130.

Rein Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.000 241.018 0.000
201609 0.000 241.428 0.000
201612 -151.910 241.432 -207.771
201703 19.402 243.801 26.279
201706 -220.398 244.955 -297.109
201709 73.387 246.819 98.183
201712 64.942 246.524 86.988
201803 55.597 249.554 73.567
201806 44.597 251.989 58.441
201809 35.320 252.439 46.202
201812 26.594 251.233 34.954
201903 17.267 254.202 22.430
201906 22.443 256.143 28.933
201909 16.403 256.759 21.096
201912 11.537 256.974 14.825
202003 7.023 258.115 8.985
202006 8.484 257.797 10.867
202009 6.248 260.280 7.927
202012 5.553 260.474 7.040
202103 13.615 264.877 16.973
202106 12.402 271.696 15.073
202109 11.064 274.310 13.319
202112 9.694 278.802 11.482
202203 7.952 287.504 9.133
202206 6.302 296.311 7.023
202209 4.998 296.808 5.561
202212 4.101 296.797 4.563
202303 3.143 301.836 3.438
202306 2.817 305.109 3.049
202309 2.466 307.789 2.646
202312 1.410 306.746 1.518
202403 2.657 312.332 2.809
202406 2.590 314.175 2.722
202409 2.318 315.301 2.428
202412 0.433 315.605 0.453
202503 0.221 319.799 0.228
202506 0.131 322.561 0.134
202509 0.047 324.800 0.048
202512 -1.019 324.054 -1.038
202603 -1.192 330.213 -1.192

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $3.74 mean?
Rein Therapeutics (RNTX) has a Cyclically Adjusted Book per Share of $3.74 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Rein Therapeutics and its competitors.
Is Rein Therapeutics' Cyclically Adjusted Book per Share too high?
Rein Therapeutics' current Cyclically Adjusted Book per Share is $3.74. Overall, Rein Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Rein Therapeutics' Cyclically Adjusted Book per Share compare to IBIO and RANI?
Rein Therapeutics' Cyclically Adjusted Book per Share of $3.74 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Rein Therapeutics and its competitors. Rein Therapeutics's current Cyclically Adjusted Book per Share is $3.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rein Therapeutics stock overvalued right now?
Rein Therapeutics (RNTX) has a current Cyclically Adjusted Book per Share of $3.74. The current Cyclically Adjusted Book per Share is $3.74. Rein Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Rein Therapeutics (RNTX), the current Cyclically Adjusted Book per Share is $3.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rein Therapeutics Business Description

Address 12407 North Mopac Expressway, Suite 250, No.390, Austin, TX, USA, 78758
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
30GF Score

Get the complete analysis for RNTX

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.99
Price